A Study to Evaluate the Safety and Phar… | Clinical Trial

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

H Plus Yangji Hospita

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Exclusion criteria

Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied

Treatment and study plan

AD-123

Drug

AD-123 Oral Tablet

AD-1231 and AD-1232

Drug

AD-1231 Oral Tablet + AD-1232 Oral Tablet

Primary outcomes

Maximum concentration of drug in plasma (Cmax)

Time frame: pre-dose to 72 hours

Cmax of AD-123
Area under the plasma concentration-time curve during dosing interval (AUCt)

Time frame: pre-dose to 72 hours

AUCt of AD-123

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Adult Volunteers Under Fasting Conditions

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Apr 20, 2026
Registry last updated: Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting